Phase I/II Trial of Atezolizumab and Cabozantinib in Recurrent Glioblastoma
A phase I/II trial is evaluating the safety and efficacy of atezolizumab combined with cabozantinib in patients with recurrent glioblastoma.
Phase I
Oncology / Glioblastoma
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing phase I/II trial of atezolizumab and cabozantinib represents a significant opportunity to address a critical gap in treatment options for recurrent glioblastoma. Positive outcomes could reshape treatment paradigms and influence competitive positioning in the oncology market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for safety and efficacy outcomes, as well as any subsequent regulatory filings.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.